Nurix Therapeutics Inc
NASDAQ:NRIX
Balance Sheet
Balance Sheet Decomposition
Nurix Therapeutics Inc
Nurix Therapeutics Inc
Balance Sheet
Nurix Therapeutics Inc
| Nov-2018 | Nov-2019 | Nov-2020 | Nov-2021 | Nov-2022 | Nov-2023 | Nov-2024 | Nov-2025 | ||
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Cash & Cash Equivalents |
25
|
35
|
119
|
80
|
65
|
55
|
110
|
247
|
|
| Cash Equivalents |
25
|
35
|
119
|
80
|
65
|
55
|
110
|
247
|
|
| Short-Term Investments |
13
|
3
|
162
|
215
|
245
|
233
|
500
|
346
|
|
| Total Receivables |
0
|
0
|
11
|
6
|
0
|
0
|
0
|
0
|
|
| Accounts Receivables |
0
|
0
|
8
|
6
|
0
|
0
|
0
|
0
|
|
| Other Receivables |
0
|
0
|
4
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
2
|
2
|
6
|
10
|
9
|
8
|
10
|
14
|
|
| Total Current Assets |
41
|
39
|
298
|
311
|
318
|
296
|
619
|
607
|
|
| PP&E Net |
4
|
4
|
7
|
25
|
30
|
48
|
46
|
73
|
|
| PP&E Gross |
4
|
4
|
7
|
25
|
30
|
48
|
46
|
73
|
|
| Accumulated Depreciation |
9
|
11
|
13
|
15
|
20
|
26
|
35
|
38
|
|
| Long-Term Investments |
0
|
1
|
91
|
137
|
64
|
7
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
3
|
5
|
5
|
4
|
8
|
|
| Total Assets |
45
N/A
|
44
-3%
|
396
+801%
|
477
+20%
|
417
-13%
|
356
-15%
|
669
+88%
|
688
+3%
|
|
| Liabilities | |||||||||
| Accounts Payable |
1
|
2
|
3
|
7
|
5
|
6
|
11
|
11
|
|
| Accrued Liabilities |
3
|
5
|
8
|
18
|
28
|
32
|
46
|
58
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
28
|
10
|
33
|
41
|
38
|
48
|
38
|
18
|
|
| Total Current Liabilities |
33
|
16
|
45
|
66
|
71
|
87
|
96
|
86
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
1
|
37
|
62
|
68
|
42
|
68
|
46
|
63
|
|
| Total Liabilities |
34
N/A
|
54
+58%
|
106
+98%
|
135
+27%
|
113
-16%
|
155
+37%
|
142
-8%
|
149
+5%
|
|
| Equity | |||||||||
| Common Stock |
48
|
48
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
39
|
61
|
104
|
221
|
401
|
545
|
739
|
1 003
|
|
| Additional Paid In Capital |
2
|
3
|
394
|
564
|
709
|
746
|
1 266
|
1 542
|
|
| Other Equity |
0
|
0
|
0
|
1
|
4
|
1
|
0
|
0
|
|
| Total Equity |
11
N/A
|
10
N/A
|
290
N/A
|
342
+18%
|
304
-11%
|
200
-34%
|
527
+163%
|
539
+2%
|
|
| Total Liabilities & Equity |
45
N/A
|
44
-3%
|
396
+801%
|
477
+20%
|
417
-13%
|
356
-15%
|
669
+88%
|
688
+3%
|
|
| Shares Outstanding | |||||||||
| Common Shares Outstanding |
11
|
11
|
39
|
45
|
47
|
49
|
76
|
102
|
|